Last Updated: November 17, 2026

Details for Patent: 12,054,498

« Back to Dashboard


Which drugs does patent 12,054,498 protect, and when does it expire?

Patent 12,054,498 protects JIDEYTRO and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 12,054,498
Title:Heteroaromatic macrocyclic ether chemotherapeutic agents
Abstract:Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
Inventor(s):Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
Assignee: Pharmaresources Co Ltd , Nuvalent Inc
Application Number:US17/834,135
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 12,054,498

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-001 Jul 22, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED AT LEAST ONE PRIOR ROS1 KINASE INHIBITOR ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-002 Jul 22, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED AT LEAST ONE PRIOR ROS1 KINASE INHIBITOR ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,054,498

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2021268664 ⤷  Start Trial
Brazil 112022022535 ⤷  Start Trial
Canada 3179700 ⤷  Start Trial
Chile 2022003045 ⤷  Start Trial
China 115916754 ⤷  Start Trial
European Patent Office 4146626 ⤷  Start Trial
Israel 297832 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.